Among the six patients who received the highest dose (10 mg), all six were alive and respiratory failure free on day 28. Positive results were also reported for patients receiving the 3 mg and 1 mg doses. Among the placebo patients by contrast, just 67% (four of six) were alive and respiratory failure free, while three showed worsening clinical status during a seven-day treatment period . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge